147 related articles for article (PubMed ID: 23797089)
1. The novel somatostatin receptor 2/dopamine type 2 receptor chimeric compound BIM-23A758 decreases the viability of human GOT1 midgut carcinoid cells.
Zitzmann K; Andersen S; Vlotides G; Spöttl G; Zhang S; Datta R; Culler M; Göke B; Auernhammer CJ
Neuroendocrinology; 2013; 98(2):128-36. PubMed ID: 23797089
[TBL] [Abstract][Full Text] [Related]
2. Efficacy of chimeric molecules directed towards multiple somatostatin and dopamine receptors on inhibition of GH and prolactin secretion from GH-secreting pituitary adenomas classified as partially responsive to somatostatin analog therapy.
Jaquet P; Gunz G; Saveanu A; Dufour H; Taylor J; Dong J; Kim S; Moreau JP; Enjalbert A; Culler MD
Eur J Endocrinol; 2005 Jul; 153(1):135-41. PubMed ID: 15994755
[TBL] [Abstract][Full Text] [Related]
3. Efficacy of a dopamine-somatostatin chimeric molecule, BIM-23A760, in the control of cell growth from primary cultures of human non-functioning pituitary adenomas: a multi-center study.
Florio T; Barbieri F; Spaziante R; Zona G; Hofland LJ; van Koetsveld PM; Feelders RA; Stalla GK; Theodoropoulou M; Culler MD; Dong J; Taylor JE; Moreau JP; Saveanu A; Gunz G; Dufour H; Jaquet P
Endocr Relat Cancer; 2008 Jun; 15(2):583-96. PubMed ID: 18509006
[TBL] [Abstract][Full Text] [Related]
4. Effects of Somatostatin Analogs and Dopamine Agonists on Insulin-Like Growth Factor 2-Induced Insulin Receptor Isoform A Activation by Gastroenteropancreatic Neuroendocrine Tumor Cells.
van Adrichem RC; de Herder WW; Kamp K; Brugts MP; de Krijger RR; Sprij-Mooij DM; Lamberts SW; van Koetsveld PM; Janssen JA; Hofland LJ
Neuroendocrinology; 2016; 103(6):815-25. PubMed ID: 26836610
[TBL] [Abstract][Full Text] [Related]
5. Effects of novel somatostatin-dopamine chimeric drugs in 2D and 3D cell culture models of neuroendocrine tumors.
Herrera-Martínez AD; van den Dungen R; Dogan-Oruc F; van Koetsveld PM; Culler MD; de Herder WW; Luque RM; Feelders RA; Hofland LJ
Endocr Relat Cancer; 2019 Jun; 26(6):585-599. PubMed ID: 30939452
[TBL] [Abstract][Full Text] [Related]
6. Somatostatin and dopamine-somatostatin multiple ligands directed towards somatostatin and dopamine receptors in pituitary adenomas.
Saveanu A; Gunz G; Guillen S; Dufour H; Culler MD; Jaquet P
Neuroendocrinology; 2006; 83(3-4):258-63. PubMed ID: 17047391
[TBL] [Abstract][Full Text] [Related]
7. BIM-23A760, a chimeric molecule directed towards somatostatin and dopamine receptors, vs universal somatostatin receptors ligands in GH-secreting pituitary adenomas partial responders to octreotide.
Jaquet P; Gunz G; Saveanu A; Barlier A; Dufour H; Taylor J; Dong J; Kim S; Moreau JP; Culler MD
J Endocrinol Invest; 2005; 28(11 Suppl International):21-7. PubMed ID: 16625841
[TBL] [Abstract][Full Text] [Related]
8. The dopamine-somatostatin chimeric compound BIM-23A760 exerts antiproliferative and cytotoxic effects in human non-functioning pituitary tumors by activating ERK1/2 and p38 pathways.
Peverelli E; Olgiati L; Locatelli M; Magni P; Fustini MF; Frank G; Mantovani G; Beck-Peccoz P; Spada A; Lania A
Cancer Lett; 2010 Feb; 288(2):170-6. PubMed ID: 19619936
[TBL] [Abstract][Full Text] [Related]
9. BIM-23A760 influences key functional endpoints in pituitary adenomas and normal pituitaries: molecular mechanisms underlying the differential response in adenomas.
Ibáñez-Costa A; López-Sánchez LM; Gahete MD; Rivero-Cortés E; Vázquez-Borrego MC; Gálvez MA; de la Riva A; Venegas-Moreno E; Jiménez-Reina L; Moreno-Carazo A; Tinahones FJ; Maraver-Selfa S; Japón MA; García-Arnés JA; Soto-Moreno A; Webb SM; Kineman RD; Culler MD; Castaño JP; Luque RM
Sci Rep; 2017 Feb; 7():42002. PubMed ID: 28181484
[TBL] [Abstract][Full Text] [Related]
10. Somatostatinergic ligands in dopamine-sensitive and -resistant prolactinomas.
Fusco A; Gunz G; Jaquet P; Dufour H; Germanetti AL; Culler MD; Barlier A; Saveanu A
Eur J Endocrinol; 2008 May; 158(5):595-603. PubMed ID: 18426817
[TBL] [Abstract][Full Text] [Related]
11. Suppression of rat and human growth hormone and prolactin secretion by a novel somatostatin/dopaminergic chimeric ligand.
Ren SG; Kim S; Taylor J; Dong J; Moreau JP; Culler MD; Melmed S
J Clin Endocrinol Metab; 2003 Nov; 88(11):5414-21. PubMed ID: 14602782
[TBL] [Abstract][Full Text] [Related]
12. Regulation of growth hormone and prolactin gene expression and secretion by chimeric somatostatin-dopamine molecules.
Gruszka A; Ren SG; Dong J; Culler MD; Melmed S
Endocrinology; 2007 Dec; 148(12):6107-14. PubMed ID: 17656461
[TBL] [Abstract][Full Text] [Related]
13. Antisecretory Effects of Chimeric Somatostatin/Dopamine Receptor Ligands on Gastroenteropancreatic Neuroendocrine Tumors.
Couvelard A; Pélaprat D; Dokmak S; Sauvanet A; Voisin T; Couvineau A; Ruszniewski P
Pancreas; 2017; 46(5):631-638. PubMed ID: 28375946
[TBL] [Abstract][Full Text] [Related]
14. TBR-760, a Dopamine-Somatostatin Compound, Arrests Growth of Aggressive Nonfunctioning Pituitary Adenomas in Mice.
Halem HA; Hochgeschwender U; Rih JK; Nelson R; Johnson GA; Thiagalingam A; Culler MD
Endocrinology; 2020 Aug; 161(8):. PubMed ID: 32591776
[TBL] [Abstract][Full Text] [Related]
15. Effects of the single and combined treatment with dopamine agonist, somatostatin analog and mTOR inhibitors in a human lung carcinoid cell line: an in vitro study.
Pivonello C; Rousaki P; Negri M; Sarnataro M; Napolitano M; Marino FZ; Patalano R; De Martino MC; Sciammarella C; Faggiano A; Rocco G; Franco R; Kaltsas GA; Colao A; Pivonello R
Endocrine; 2017 Jun; 56(3):603-620. PubMed ID: 27688013
[TBL] [Abstract][Full Text] [Related]
16. Bim-23244, a somatostatin receptor subtype 2- and 5-selective analog with enhanced efficacy in suppressing growth hormone (GH) from octreotide-resistant human GH-secreting adenomas.
Saveanu A; Gunz G; Dufour H; Caron P; Fina F; Ouafik L; Culler MD; Moreau JP; Enjalbert A; Jaquet P
J Clin Endocrinol Metab; 2001 Jan; 86(1):140-5. PubMed ID: 11231991
[TBL] [Abstract][Full Text] [Related]
17. Effects of chimeric somatostatin-dopamine molecules on human peripheral blood lymphocytes activation.
Casnici C; Lattuada D; Crotta K; Mastrotto C; Franco P; Culler MD; Marelli O
J Neuroimmunol; 2006 Oct; 179(1-2):9-17. PubMed ID: 16904194
[TBL] [Abstract][Full Text] [Related]
18. Somatostatin and dopamine receptor interaction in prostate and lung cancer cell lines.
Arvigo M; Gatto F; Ruscica M; Ameri P; Dozio E; Albertelli M; Culler MD; Motta M; Minuto F; Magni P; Ferone D
J Endocrinol; 2010 Dec; 207(3):309-17. PubMed ID: 20876239
[TBL] [Abstract][Full Text] [Related]
19. Somatostatin and dopamine receptor expression in lung carcinoma cells and effects of chimeric somatostatin-dopamine molecules on cell proliferation.
Ferone D; Arvigo M; Semino C; Jaquet P; Saveanu A; Taylor JE; Moreau JP; Culler MD; Albertelli M; Minuto F; Barreca A
Am J Physiol Endocrinol Metab; 2005 Dec; 289(6):E1044-50. PubMed ID: 16046458
[TBL] [Abstract][Full Text] [Related]
20. Balance between somatostatin and D2 receptor expression drives TSH-secreting adenoma response to somatostatin analogues and dopastatins.
Gatto F; Barbieri F; Gatti M; Wurth R; Schulz S; Ravetti JL; Zona G; Culler MD; Saveanu A; Giusti M; Minuto F; Hofland LJ; Ferone D; Florio T
Clin Endocrinol (Oxf); 2012 Mar; 76(3):407-14. PubMed ID: 21848909
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
